A major limitation of cell therapies is the rapid decline in viability and function of the transplanted cells. Here we describe a strategy to enhance cell therapy via the conjugation of adjuvant drug-loaded nanoparticles to the surfaces of therapeutic cells. With this method of providing sustained pseudoautocrine stimulation to donor cells, we elicited marked enhancements in tumor elimination in a model of adoptive T cell therapy for cancer. We also increased the in vivo repopulation rate of hematopoietic stem cell grafts with very low doses of adjuvant drugs that were ineffective when given systemically. This approach is a simple and generalizable strategy to augment cytoreagents while minimizing the systemic side effects of adjuvant drugs. In addition, these results suggest therapeutic cells are promising vectors for actively targeted drug delivery.
Cell-based therapies, such as hematopoietic stem cell (HSC), islet cell or hepatocyte transplants, are in routine clinical practice 1, 2 , and new treatment strategies implementing adult, embryonic or induced pluripotent stem cells are in various stages of development 3, 4 . In the field of cancer immunotherapy, early clinical trials infusing ex vivoexpanded tumor-specific T lymphocytes have yielded promising results for the treatment of cancer and chronic infections [5] [6] [7] . Notably, after cell transfer, therapeutic cells often rely on the concurrent delivery of adjuvant drugs. These agents are designed to maximize donor cell efficacy and in vivo persistence, offset suppressive molecules at cell homing sites and promote the differentiation of transferred cells into a therapeutically optimal phenotype. Examples include γ c receptor cytokines 5, 8 or transforming growth factor-β signaling inhibitors 9 in adoptive T cell therapy or the use of small-molecule drugs to boost immune reconstitution after HSC transplants 10 . However, these agents often need to be maintained at high and sustained systemic levels for efficacy. This leads to dose-limiting toxicities for these drugs due to their generally pleiotropic activity, which has restricted their clinical use 11, 12 . One approach to focus adjuvant drug action on the transferred cells is to genetically engineer donor cells to secrete their own supporting factors 13 . However, the regulatory and cost barriers of large-scale production and safety testing of clinical-grade vectors, costly and lengthy cell culture protocols and the technical challenges of efficient gene transfer hinder the implementation of clinical gene therapy protocols. Furthermore, several emerging adjuvant therapies are based on small-molecule drugs that cannot be genetically encoded 9, 10 . Here we describe an alternate strategy for adjuvant drug delivery in cell therapies based on chemical conjugation of submicron-sized drug-loaded synthetic particles directly onto the plasma membrane of donor cells, enabling continuous pseudoautocrine stimulation of transferred cells in vivo.
RESULTS

Stable nanoparticle attachment to cell surfaces
To stably couple synthetic drug-carrier nanoparticles to the surface of therapeutic cells, we exploited the fact that many cells have high levels of reduced thiol groups on their surfaces 14 . Confirming previous reports 14 , we detected substantial amounts of free thiols on the surfaces of T cells, B cells and HSCs but low amounts on red blood cells (Fig. 1a) . To link synthetic drug carriers to cells via these surface thiols, we used liposomes and liposome-like synthetic nanoparticles 100-300 nm in diameter with a drug-loaded core and phospholipid surface layer, in which the lipid bilayer surface of the particles included thiol-reactive maleimide headgroups (Supplementary Fig. 1 ). We achieved particle conjugation by a simple two-step process (Fig. 1b) : we first incubated donor cells with nanoparticles to permit maleimide-thiol coupling, followed by in situ conjugation to thiol-terminated polyethylene glycol (PEGylation) to quench residual reactive groups of the particles ( Supplementary  Fig. 2 ). With this approach, we could covalently link a substantial number of nanoparticles with diameters in the 100-300 nm range to cell types used commonly in cell therapy, including CD8 + T lymphocytes or lineage − Sca-1 + c-Kit + HSCs (Fig. 1c) . Particles ranging from simple liposomes (with an aqueous drug-loaded core) to more complex multilamellar lipid nanoparticles or lipid-coated polymer nanoparticles 15 ( Fig. 1c and Supplementary Figs. 1 and 3) were stably attached to live cells. Notably, particle coupling was benign, as coupling of up to 140 (± 30) ~200-nm multilamellar lipid nanoparticles to the surface of cells was nontoxic ( Supplementary Fig. 4 ) and blocked only 17.2% (± 8.7%) of the total available cell surface thiol groups (Supplementary Fig. 5 ). These findings are consistent with a simple calculation of the surface area occupied by the nanoparticles: attachment of 150 particles, each 200 nm in diameter, would occlude only 3% of the surface of a typical 7-μm-diameter T cell.
Although liposomes and lipid-coated polymer particles spontaneously adsorbed to cell surfaces, we found that physically adsorbed particles could be removed during mild cell washing steps, whereas maleimide-linked particles remained stably bound to cells (Fig. 1d) . Attachment of nanoparticles to T cells did not trigger spontaneous activation of the cells (Supplementary Fig. 6 ), and particles bound to lymphocytes or HSCs remained localized at the cell surface, as revealed by optical sectioning with confocal microscopy ( Fig. 1c and Supplementary Movies 1 and 2) and by flow cytometry internalization assays (Fig. 1e) , even after extended in vitro stimulation (Fig. 1c) . In contrast, we observed that phagocytic cells such as immature dendritic cells efficiently internalized maleimide-functionalized nanoparticles after a short incubation (Fig. 1e) . Although all three types of nanoparticles tested here conjugated to lymphocytes with comparable efficiencies, we chose to focus on ~300-nm multilamellar lipid nanoparticles (Supplementary Fig. 1b ) for our subsequent in vitro functional and in vivo therapeutic studies on the basis of their high drug encapsulation efficiencies and week-long drug release profiles and the lack of inflammatory responses elicited from innate immune cells exposed to the 'empty' particles ( Supplementary Figs. 7 and 8) .
Nanoparticle conjugation does not alter key cellular functions
We next determined the maximum number of particles (without encapsulated drug cargo) that could be linked to cells without compromising key cellular functions, focusing on therapeutic cytotoxic T cells that must be capable of forming an immunological synapse and killing target cells, proliferating and secreting cytokines as part of their normal function. Ovalbumin-specific T cell receptor-transgenic OT-1 CD8 + T cells conjugated with up to 100 (± 20) nanoparticles per cell retained an unmodified proliferative response after co-culture with ovalbumin-pulsed dendritic cells; higher surface densities of particles began to inhibit T cell proliferation (Fig. 2a, and Supplementary  Fig. 9a,b) . During cell division, surface-attached nanoparticles segregated equally to daughter cells, reflected by a stepwise decrease in the mean fluorescence emitted from cell-conjugated nanoparticles with increasing number of divisions ( Figs. 1c and 2a) . Attachment of ~100 particles per cell also did not affect T cell recognition or killing of ovalbumin peptide-pulsed target cells or cytokine release profiles ( Fig. 2b and Supplementary Fig. 9c ). We next assessed the impact of cell surface-tethered nanoparticles on T cell transmigration across endothelial monolayers-a key capability of any therapeutic cell to efficiently infiltrate its target tissue. We first used an in vitro transwell co-culture system and quantified the migration of nanoparticleconjugated T lymphocytes across a membrane-supported confluent endothelial monolayer in response to a chemoattractant placed in the lower chamber. T cells carrying 100 nanoparticles per cell showed unaltered transmigration efficiencies compared to unmodified cells (Fig. 2c) . After crossing the endothelial barrier, T cells retained 83% (± 3%) of their original nanoparticle cargo physically attached (Fig. 2d) . (In comparative experiments, liposomes and lipid-coated poly(lactic-co-glycolic acid) particles could also be carried through endothelial layers by T cells, although poly(lactic-co-glycolic acid) particles were not retained as well by transmigrating cells and showed a tendency to inhibit T cell transmigration at high particle-per-cell loadings; Supplementary Fig. 10 ).
To determine whether in vivo tissue homing of T cells was affected by nanoparticle conjugation, we evaluated the tumor-homing properties of particle-conjugated lymphocytes (Fig. 3) . Subcutaneous EL4 tumors expressing membrane-bound Gaussia luciferase (extG-luc) and ovalbumin (EG7-OVA) or exG-luc alone were established on opposite flanks of C57BL/6 mice. Tumor-bearing mice then received adoptive transfers of firefly luciferase (F-luc)-transgenic OT-1 T cells with or without surface-conjugated red fluorescent nanoparticles or an intravenous (i.v.) injection of an equivalent dose of fluorescent particles alone. Particle-carrying OT-1 T cells specifically trafficked to EL4-OVA tumors (Fig. 3a) , and we observed no difference in the tumor-homing potential of particle-conjugated compared to unmodified OT-1 T cells (Fig. 3b) . Quantitative fluorescent particle imaging of EG7-OVA tumors indicated that nanoparticles accumulated 176-fold more efficiently at the tumor site when they were attached to the surface of OT-1 T cells compared to systemically infused free nanoparticles, which were rapidly scavenged by the liver and the spleen (Fig. 3b,d) . Flow cytometry analysis independently verified that T cell infiltration of EG7-OVA tumors was quantitatively identical for particle-decorated and control OT-1 cells and that the majority of particle-conjugated cells recovered from tumors still retained their nanoparticle cargo (Fig. 3a) . In separate experiments with fluorescently labeled OT-1 T cells, we confirmed prominent infiltration of nanoparticle-decorated T cells into EG7-OVA tumors in histological tumor sections examined by confocal microscopy, and nanoparticles appeared to be localized to the surface, as observed in vitro (Fig. 3c, Supplementary Fig. 11 and Supplementary Movies 3 and 4). Of note, the ability of lymphocytes to efficiently transfer surface-tethered nanoparticles across endothelial barriers in vivo was not restricted to the abnormal endothelial lining 16 found in tumor vasculature (Supplementary Fig. 12 ). When we linked particles to resting B cells expressing CC-motif chemokine receptor-7 and CD62 ligand (CD62L) (Supplementary Fig. 12 ) or central memory CD8 + T cells (data not shown), particles were transported across the intercellular boundaries of high endothelial venules into lymph nodes-a poorly accessible compartment for systemically infused free nanoparticles.
Targeted cytokine support of antitumor T cells
We next tested whether cell-bound adjuvant drug-loaded nanoparticles could directly impart amplified therapeutic functions to their cellular carriers by treating established, disseminated B16F10 melanoma lung and bone marrow metastases with adoptively transferred melanoma-specific Pmel-1 CD8 + T cells 17 . We encapsulated a mixture of the cytokines interleukin-15 (IL-15) (converted to a superagonist (IL-15Sa) by precomplexing with soluble IL-15 receptor α 18 ) and IL-21 into multilamellar lipid nanoparticles. These two interleukins cooperatively promote in vivo T cell expansion and effector function when administered daily at high doses 8 . Particles ~300 nm in diameter efficiently entrapped IL-15Sa and IL-21 and released bioactive cytokine over a 7-d period (Supplementary Fig. 13 ). These cytokine-loaded particles were conjugated to CD8 + Pmel-1 effector T cells expressing click beetle red (CBR)-luciferase (CBR-luc). Particleconjugated or control T cells were infused into lymphodepleted mice bearing established Gaussia luciferase-expressing B16F10 melanoma lung and bone marrow tumors (Fig. 4a) . Serial imaging of nonadjuvanted Pmel-1 T cells showed a gradual CBR-luc signal decline after T cell injection, consistent with poor in vivo T cell expansion and persistence (Fig. 4a-c) . Whereas a single systemic infusion of 5 μg free cytokine (4.03 μg IL-15Sa plus 0.93 μg IL-21) given on the day of adoptive transfer did not significantly boost Pmel-1 proliferation (1.4-fold higher CBR-luc signal on day 6, P = 0.32), the same cytokine dose loaded in cell-bound nanoparticles elicited markedly amplified proliferation by Pmel-1 cells (81-fold higher peak photon count relative to unmodified Pmel-1 T cells on day 6, P < 0.0001, Fig. 4a,c) . Subsequent to a contraction period, cytokine nanoparticlecarrying T cells showed enhanced long-term persistence (14.8-fold and 4.7-fold higher photon counts than Pmel-1 T cells alone at 16 and 30 d after T cell infusion, respectively, P < 0.0001) and homed as CD44 + CD62L + central memory T cells to lymph nodes and spleen (Fig. 4a,b and Supplementary Fig. 14) .
Notably, experiments comparing the in vivo proliferative response of T cells bearing cytokine-loaded nanoparticles and bystander tumor-homing T cells showed that nanoparticle-released cytokines activated T cells primarily in cis, with limited paracrine stimulation of bystander cells (Supplementary Fig. 15) . The adjuvant effect of T cell-conjugated cytokine nanoparticles was largely tumor antigen independent (Supplementary Fig. 16b,d) , consistent with earlier studies demonstrating antigen-independent proliferation of T cells in response to IL-15 (ref. 19 ), but there was no evidence of progressive T cell clonality or leukemia formation in any treated mouse imaged at late time points (data not shown). Of note, cytokine-loaded particles concurrently injected but not attached to T cells elicited a 4.9-fold higher peak Pmel-1 T cell proliferation compared to the same cytokine dose administered in an unencapsulated soluble form (day 6, P = 0.0052), but this stimulatory effect was still only 9% of that obtained by linking the same number of cytokine-loaded nanoparticles directly to the surface of the adoptively transferred T cells (P < 0.0001, Supplementary Fig. 16c,d ). Pmel-1 T cells conjugated with empty nanoparticles showed the same expansion and decline in vivo as unmodified Pmel-1 cells (Supplementary Fig. 16a,d ). All mice receiving cytokine nanoparticle-decorated Pmel-1 T cells achieved complete tumor clearance (Fig. 4a,d ), whereas treatment with Pmel-1 T cells with or without systemic cytokine infusion at the same doses as encapsulated in nanoparticles yielded only modest survival advantages (Fig. 4a,d) . We also investigated the in vivo tumor eradication potential of cytokine nanoparticle-conjugated Pmel-1 T lymphocytes in mice bearing large, established subcutaneous B16F10 flank tumors. Mice treated with unmodified Pmel-1 T lymphocytes uniformly succumbed to tumors within 30 d, whereas the infusion of cytokine nanoparticledecorated Pmel-1 T cells prevented tumor growth, with all mice alive 30 d after T cell treatment (Supplementary Fig. 17 ).
Enhanced repopulation kinetics of HSC transplants
Prompted by the substantial therapeutic benefits achieved with conjugation of cytokine-loaded particles to tumor-specific T cells, we further examined the utility of this new adjuvant delivery approach in the context of hematopoietic stem cell transplantations. We chose the glycogen synthase kinase-3β (GSK-3β) inhibitor TWS119 (ref. 20) as therapeutic cargo on the basis of reports that repeated high-dose bolus therapy of transplant recipients with GSK-3 inhibitors enhances the repopulation kinetics of donor HSCs 10 . Multilamellar lipid nanoparticles efficiently encapsulated this small-molecule drug and slowly released it over a 7-d time period (Supplementary Fig. 13 ).
We evaluated the in vivo repopulation capabilities of hematopoietic grafts supported by cell-bound, TWS119-loaded nanoparticles on the basis of the whole-body photon emission from firefly luciferase-transgenic donor HSCs and, in separate experiments, by tracing the frequencies of GFP + donor HSCs by flow cytometry. After transplanting of lineage − Sca-1 + c-Kit + HSCs from luciferasetransgenic donors into lethally irradiated syngeneic recipients, we observed a steady increase in whole-body bioluminescent emission originating from discrete foci over anatomic sites corresponding to the femurs, humeri, sternum and spleen (Fig. 5a) . Whereas a systemic TWS119 bolus injection (1.6 ng) at the time of transplantation did not substantially alter measured engraftment kinetics (Fig. 5a,b) , the same TWS119 dose encapsulated in nanoparticles surface tethered to donor HSCs significantly enhanced reconstitution by HSC grafts (median 5.7-fold higher bioluminescence than systemic TWS119 after 1 week, P < 0.0001, Fig. 5a-c) . Notably, mice in all treatment groups initially engrafted HSCs in both femurs and the sternum, indicating that nanoparticle conjugation did not compromise the intrinsic homing properties of donor HSCs. Although conjugating TWS119 nanoparticles onto HSCs increased the rate of initial reconstitution, it did not affect their multilineage differentiation potential, reflected by a similar frequency of donor-derived GFP + reconstituted cell types compared to control HSC grafts 3 months after transplantation (Fig. 5d) . Thus, this simple approach for donor cell modification just before cell transfer can also augment HSC transplants, a procedure in routine clinical practice.
DISCUSSION
Cell therapies (for example, HSC and islet cell transplants) are in common clinical practice and are also being aggressively developed in other areas of medicine, such as adoptive T cell therapy of cancer [5] [6] [7] . However, many cell therapy protocols rely on adjuvant drugs that act directly on the transferred therapeutic cells to maintain their function, phenotype and/or lifespan. A ubiquitous challenge is the pleiotropic activity of many biological and smallmolecule drugs, leading to toxicity or unwanted side effects after systemic exposure. This problem is illustrated by the use of IL-2 in the support of adoptive T cell therapy of melanoma, where IL-2 provides key adjuvant signals to donor T cells but also elicits severe dose-limiting toxicity 12 .
Here we devised a simple, generalizable and clinically applicable strategy to augment the therapeutic potential of cytoreagents while limiting the potential for side effects from adjuvant drugs. We showed that adjuvant agent-releasing particles can be stably conjugated to cells without toxicity or interference with intrinsic cell functions, follow the characteristic in vivo migration patterns of their cellular vehicles and, ultimately, endow their carrier cells with substantially enhanced function using low drug doses that have no effect when given by traditional systemic routes. Prolonged retention of the particles on the surfaces of donor cells as shown here enables sustained drug release without concerns of premature degradation of the particle carrier or cargo owing to internalization into degradative intracellular compartments. Notably, previous work has shown that particles ~200 nm in diameter coated with antibody to CD3 are readily internalized by T cell lines 21 , suggesting that internalization of particles in the size range studied here is not impossible for lymphocytes per se. Thus, elucidating the mechanisms regulating prolonged particle retention on T cell and HSC surfaces is an area for future study. Numerous reports have illustrated the potential of systemically infused nanoparticle materials slowly releasing drug cargos to enhance the efficacy of therapeutic drugs, and this has led to the development of clinical products such as anthracycline-loaded liposomes for cancer therapy 22 . However, in the context of support for cell therapy, our data demonstrate that conjugation of drug-loaded particles directly to the donor cells markedly increases their therapeutic impact. This strategy does not require cell preconditioning and complements traditional genetic engineering or chemical biology approaches 23 to augment or reprogram cell function. Given the wealth of available nanoparticle formulations tailored to deliver small molecule drugs, proteins, siRNA or magnetic imaging agents [24] [25] [26] [27] , the range of therapeutic or diagnostic cargos that can be attached to therapeutic cells probably extends far beyond the small molecules and recombinant proteins illustrated here.
Our study further demonstrates the concept of cells as chaperones that actively direct drug-loaded nanoparticles into poorly accessible anatomical compartments. In the field of cancer therapy, targeting strategies functionalizing drugs or biomaterials with specific tumortargeting ligands, such as antibodies, aptamers, small molecules or folic acid, have been shown to improve therapeutic efficacy [28] [29] [30] . However, these approaches generally rely on the initially passive accumulation of targeted therapeutics at tumor sites via the enhanced permeation and retention effect 27 , and it has been shown in some systems that targeting ligands do not change the overall tissue biodistribution of i.v.-delivered nanoparticle drug carriers but rather enable those particles that do reach tumors to be more efficiently internalized by target cells 28, 31 . In contrast, cellular nanoparticle vectors actively transmigrate the endothelial barrier and accumulate cell-attached cargo in tissues at more than two-log greater levels than systemically infused free particles. This profoundly altered biodistribution opens new venues, beyond existing cell therapies, for applications of cell products as actively targeting drug delivery 'pharmacytes' or vaccine delivery tools. 
ONLINE METHODS
Cell lines. The mouse melanoma cell line B16F10, the mouse pancreatic islet endothelial cell line MS1, the mouse thymoma cell line EL4 and EG7-OVA, an EL4 cell line stably transfected with the plasmid pAc-neo-OVA which carries a complete copy of chicken ovalbumin (OVA) mRNA, were all purchased from the American Type Culture Collection. We purchased the Phoenix Eco retroviral packaging cell line from Orbigen. For bioluminescent in vivo tumor imaging, we retrovirally transduced the B16F10, EL4 and EG7-OVA cell lines with a membrane-anchored form of the Gaussia luciferase (extG-Luc), provided to us by M. Sadelain, as described in the Supplementary Methods.
Mice and in vivo tumor models. Mice were housed in the MIT Animal Facility. We performed all mouse studies in the context of an animal protocol approved by the MIT Division of Comparative Medicine following federal, state and local guidelines. C57BL/6 mice, C57BL/6 Pmel-1-Thy1.1 mice, OT-1 transgenic mice and C57BL/6 GFP-transgenic mice were all obtained from Jackson Laboratories. C57BL/6 (H-2K b , Thy-1.1) firefly luciferase (F-luc)-transgenic mice 32 were provided to us by M. van den Brink. For adoptive T cell experiments with ovalbumin-specific transgenic T cells, we subcutaneously injected C57BL/6 mice with 4 × 10 6 EG7-OVA tumor cells into the right flank and 2 × 10 6 control EL4 cells into the left flank to generate equally sized s.c. tumors 7 d later. We retrovirally transduced both tumor cell lines with extG-luc for bioluminescent imaging. To establish melanoma lung tumor metastases, we injected 1 × 10 6 B16F10-extG-luc tumor cells i.v. via the tail vein into C57BL/6 mice 1 week before T cell treatment. On the day of adoptive Pmel-1 T cell transfer, we sublethally irradiated recipient mice with 500 cGy of total body irradiation from a 137 Cs source. All mice were treated with a single infusion of 1.5 × 10 7 effector CD8 + T cells.
Preparation of primed T cells for adoptive transfer and retroviral transduction.
Spleens were collected, macerated over a filter, and resuspended in ACK lysing Buffer (Biosource). In all, we placed 3 × 10 6 splenocytes per milliliter in complete RPMI 1640 with 1 ng ml −1 IL-7 and 2 μg ml −1 concavalin A (Calbiochem) and incubated at 37 °C. Two days later, we removed dead cells by Ficoll gradient (GE Healthcare) and isolated CD8 + cells with a mouse CD8 Negative Isolation Kit (Stemcell Technologies). We then preloaded 1 ml per well of concentrated retrovirus (Supplementary Methods) on sixwell non-tissue-culture-treated dishes coated with RetroNectin (TakiraBio) and incubated them at 37 °C incubation for 1 h. An equal volume of isolated T cells (3 × 10 6 cells per ml substituted with 50 international units human IL-2 per ml) was added and centrifuged at 2,000g for 30 min. Six hours after 'spinoculation' , 1 ml of fresh, prewarmed RPMI, containing 50 international units human IL-2 (Chiron) was added. We used T cells for adoptive transfer experiments 1 d after gene transfer.
Nanoparticle conjugation with cells and in situ PEGylation. Detailed information on nanoparticle and liposome synthesis as well as cytokine and smallmolecule particle loading is included in the Supplementary Methods. We resuspended 6 × 10 7 cells per ml in serum-free X-Vivo 10 medium (Cambrex) after two PBS washes. We then added an equal volume of nanoparticles in nuclease-free water, with 1, 200, 600, 300 or 150 nanoparticles per T cell (resulting in 139 ± 29, 128 ± 23, 100 ± 21 or 75 ± 32 surface-tethered particles per T cell, respectively, after cell washes and PEGylation), and incubated the cells at 37 °C for 30 min with gentle agitation every 10 min. After a PBS wash to separate cells from unbound particles, we quenched residual maleimide groups on cell-bound particles by incubation of 3 × 10 6 cells per ml with 1 mg ml −1 thiol-terminated 2-kDa PEG (Laysan Bio) at 37 °C for 30 min in complete RPMI medium, followed by two PBS washes to remove unbound PEG.
We found 1 mg ml −1 thiol-PEG to be the optimal concentration required to quench all remaining maleimide groups on nanoparticles after cell conjugation on the basis of little FACS signal after a 30-min incubation with 70 mg ml −1 BODIPY-tagged cysteine (generated from reduction of the disulfide bond in BODIPY l-cystine (Invitrogen) with a 15-molar excess of HCl Tris(2-carboxyethyl) phosphine hydrochloride (Thermo Scientific) for 45 min at 37 °C). The nanoparticle binding efficiency of maleimide-functionalized (50 mol% 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl) butyramide] in the lipid fraction) multilamellar lipid nanoparticles to effector T lymphocytes was 33.4% (± 6.9%), when incubating 500 particles per T cell, as determined by high-magnification confocal microscopy imaging of 30 single T cell Z-stacks. We distinguished between surface-conjugated and internalized nanoparticles by flow cytometry internalization assay, described in the Supplementary Methods. Statistical analyses. We used the unpaired Student's t test to test the difference between bioluminescent signals and the log-rank test to analyze survival data. All statistical analysis was performed using Prism 4.0 software. 
